ABLYNX WILL RECEIVE FURTHER MILESTONE PAYMENTS OF ?3 MILLION AS PART
OF ITS STRATEGIC ALLIANCE WITH
(Thomson Reuters ONE) - GHENT, Belgium, 2 December 2009 - Ablynx [Euronext Brussels: ABLX]today announced that it will receive further milestone paymentstotalling ?3 million from Boehringer Ingelheim, triggered as part ofits strategic alliance for the development and commercialisation ofNanobodies®. Ablynx will now have earned a total of ?9 million inmilestone payments from Boehringer Ingelheim in 2009.Ablynx and Boehringer Ingelheim entered into an agreement inSeptember 2007 to collaborate on the discovery, development andcommercialisation of up to 10 different Nanobody therapeutics acrossa range of multiple therapeutic areas including for exampleimmunology, oncology and respiratory diseases. The agreement wouldallow potential milestone payments of up to ?125 million for eachNanobody developed as well as undisclosed royalties to Ablynx.Boehringer Ingelheim is exclusively responsible for the development,manufacture and commercialisation of any products resulting from thecollaboration. Ablynx retains certain co-promotion rights in Europe.Dr Edwin Moses, CEO and Chairman of Ablynx, said:"Achieving three research-based milestones in less than one yeardemonstrates the significant progress made in our strategic alliancewith Boehringer Ingelheim. We are delighted to see that the Nanobodyplatform delivers across multiple therapeutic areas and in complextarget programmes." He added: "We look forward to seeing theseNanobody programmes progressing towards development." -ends-About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.comFounded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceuticalcompany focused on the discovery and development of Nanobodies, anovel class of therapeutic proteins based on single-domain antibodyfragments, for a range of serious and life-threatening humandiseases. The Company currently has over 230 employees. Ablynxcompleted a successful IPO on Euronext Brussels [ABLX] on 7 November2007.Ablynx is developing a portfolio of Nanobody-based therapeutics in anumber of major disease areas, including inflammation, thrombosis,oncology and Alzheimer's disease. Nanobodies have been generatedagainst more than 150 different disease targets. Efficacy data havebeen obtained in over 26 in vivo models for Nanobodies against arange of different targets.For more information, please contact:College Hill Life Sciences - for International media enquiries:Sue Charles, Justine Lamond, Dr John McIntyret: +44 (0)20 7866 7857f: +44 (0)20 7866 7900e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comhttp://hugin.info/137912/R/1358802/330976.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 02.12.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 9173
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 424 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX WILL RECEIVE FURTHER MILESTONE PAYMENTS OF ?3 MILLION AS PART
OF ITS STRATEGIC ALLIANCE WITH "
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
